| Pharmaceutical Information |
| Drug Name |
Samarium sm-153 lexidronam pentasodium |
| Drug ID |
BADD_D01986 |
| Description |
Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. |
| Indications and Usage |
Investigated for use/treatment in bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis. |
| Marketing Status |
approved; investigational |
| ATC Code |
V10BX02 |
| DrugBank ID |
DB05273
|
| KEGG ID |
D08504; D05795
|
| MeSH ID |
C061972
|
| PubChem ID |
9810246
|
| TTD Drug ID |
D0R3BC
|
| NDC Product Code |
Not Available |
| UNII |
7389YR3OOV
|
| Synonyms |
samarium Sm-153 lexidronam | samarium-153-EDTMP | 153Sm-EDTMP | samarium-153 lexidronam | samarium (153Sm) lexidronam | samarate(5-)-153Sm, (((1,2-ethanediylbis((nitrilo-kappa-N)bis(methylene)))tetrakis(phosphonato-kappa-O))(8-))-, pentahydrogen, (oc-6-21) | Quadramet | samarium ethylenediaminetetramethylenephosphonate | Sm-EDTMP |
|
| Chemical Information |
| Molecular Formula |
C6H12N2Na5O12P4Sm |
| CAS Registry Number |
176669-18-4 |
| SMILES |
C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+]
.[Na+].[Na+].[Na+].[Na+].[Sm+3] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
